Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival...
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
SAGE Publishing
2023-06-01
|
| coleção: | Therapeutic Advances in Medical Oncology |
| Acesso em linha: | https://doi.org/10.1177/17588359231175440 |